Gene therapy corrects sickle cell disease in laboratory study

December 04, 2008

New St. Jude treatment alleviates long-term anemia and organ damage in mice and paves the way for human applications

Using a harmless virus to insert a corrective gene into mouse blood cells, scientists at St. Jude Children's Research Hospital have alleviated sickle cell disease pathology. In their studies, the researchers found that the treated mice showed essentially no difference from normal mice. Although the scientists caution that applying the gene therapy to humans presents significant technical obstacles, they believe that the new therapy will become an important treatment for the disease.

Sickle cell disease, which affects millions of people worldwide, arises because of a tiny genetic defect in the gene for beta-globin, a protein component of hemoglobin. This defect causes hemoglobin-containing red blood cells to tend to deform, clump and break apart. The resulting clogged blood vessels can lead to cognitive dysfunction by causing small strokes in the brain and cause damage to kidneys, liver, spleen and lungs. The only permanent cure for the disease is a bone marrow transplant to give recipients blood-forming cells that will form normal beta-globin. However, such transplants are rare because of the lack of compatible donors.

Researchers have long known that symptoms of the disease could be alleviated by persistence in the blood of an immature fetal form of hemoglobin in red blood cells. This immature hemoglobin, which usually disappears after birth, does not contain beta-globin, but another form called gamma-globin. St. Jude researchers had found that treating patients with the drug hydroxyurea encourages the formation of fetal hemoglobin and alleviates disease symptoms.

"While this is a very useful treatment for the disease, our studies indicated that it might be possible to cure the disorder if we could use gene transfer to permanently increase fetal hemoglobin levels," said Derek Persons, M.D., Ph.D., assistant member in the St. Jude Department of Hematology.

He and his colleagues developed a technique to insert the gene for gamma-globin into blood-forming cells using a harmless viral carrier. The researchers extracted the blood-forming cells, performed the viral gene insertion in a culture dish and then re-introduced the altered blood-forming cells into the body. The hope was that those cells would permanently generate red blood cells containing fetal hemoglobin, alleviating the disease.

In the experiments, reported in the advanced, online issue of the journal Molecular Therapy, the researchers used a strain of mouse with basically the same genetic defect and symptoms as humans with sickle cell disease. The scientists introduced the gene for gamma-globin into the mice's blood-forming cells and then introduced those altered cells into the mice.

The investigators found that months after they introduced the altered blood-forming cells, the mice continued to produce gamma-globin in their red blood cells.

"When we examined the treated mice, we could detect little, if any, disease using our methods," said Persons, the paper's senior author. "The mice showed no anemia, and their organ function was essentially normal."

The researchers also transplanted the altered blood-forming cells from the original treated mice into a second generation of sickle cell mice to show that the gamma-globin gene had incorporated itself permanently into the blood-forming cells. Five months after that transplantation, the second generation of mice also showed production of fetal hemoglobin and correction of their disease.

"We are very encouraged by our results," Persons said. "They demonstrate for the first time that it is possible to correct sickle cell disease with genetic therapy to produce fetal hemoglobin. We think that increased fetal hemoglobin expression in patients will be well tolerated and the immune system would not reject the hemoglobin, in comparison to other approaches."

While Persons believes that the mouse experiments will lead to treatments in humans, he cautioned that technical barriers still need to be overcome. "It is far easier to achieve high levels of gene insertion into mouse cells than into human cells," he said. "In our mouse experiments, we routinely saw one or two copies of the gamma-globin gene inserted into each cell. However, in humans this insertion rate is at least a hundred-fold less."

Persons' laboratory is currently working with other animal and human cells to develop methods to achieve a high enough gene insertion rate to make the gene therapy clinically useful.

St. Jude Children's Research Hospital

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (Steinberg, Disorders of Hemoglobin)
by Martin H. Steinberg (Author), Bernard G. Forget (Author), Douglas R. Higgs (Author), David J. Weatherall (Author)

This book is a completely revised new edition of the definitive reference on disorders of hemoglobin. Authored by world-renowned experts, the book focuses on basic science aspects and clinical features of hemoglobinopathies, covering diagnosis, treatment, and future applications of current research. While the second edition continues to address the important molecular, cellular, and genetic components, coverage of clinical issues has been significantly expanded, and there is more practical emphasis on diagnosis and management throughout. The book opens with a review of the scientific underpinnings. Pathophysiology of common hemoglobin disorders is discussed next in an entirely new section devoted to vascular biology, the erythrocyte membrane, nitric oxide biology, and hemolysis. Four...

Hemoglobin: Molecular, Genetic and Clinical Aspects
by H. Franklin Bunn (Author), Bernard G. Forger (Author)

Hemoglobin Disorders: Molecular Methods and Protocols (Methods in Molecular Medicine)
by Ronald L. Nagel (Editor)

A collection of readily reproducible experimental and clinical techniques for studying the molecular basis of hemoglobin disorders. These step-by-step methods utilize a wide variety of the latest analytical techniques, including x-ray crystallography, high performance liquid chromatography, electrophoresis, and nuclear magnetic resonance. Additional methods are offered for prenatal diagnostic analysis, the DNA diagnosis of hemoglobin mutations, hemoglobin fluorescence, and the semisynthesis of hemoglobin.

Hemoglobin: Cooperativity and Electronic Properties (Molecular Biology, Biochemistry and Biophysics, Vol 15)
by M. Weissbluth (Author)

The 2010-2015 World Outlook for Hemoglobin (Hb) A1c Monitoring Equipment
by Icon Group International (Author)

This econometric study covers the world outlook for hemoglobin (Hb) A1c monitoring equipment across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might...

Glycosylated Hemoglobins: Methods of Analysis and Clinical Applications (Chemical and Biochemical Analysis Series, Vol 19)
by E. C. Abraham (Author)

Hemoglobin-based Oxygen Carriers (HBOCs): The Future in Resuscitation? An Issue of Critical Care Clinics, 1e (The Clinics: Nursing)
by Lena M. Napolitano MD (Author)

Hemoglobin-based Oxygen Carriers is an exciting and evolving alternative to blood transfusion. This issue explores its potential with topics on: "HBOCs from Human or Bovine Hemoglobin", "Comparison of HBOCs to Stored Human Red Blood Cells," "HBOCs and Tissue Oxygenation," "HBOCs: Role in surgery, resuscitation or hemorrhagic shock?" and more!

Guidelines for Transfusion of Erythrocytes Containing Sickle Hemoglobin
by Jerald E. Mullersman (Author), MD (Author), PhD (Author), Gary E. Carnahan (Author)

Circumstances under which blood from donors with sickle cell trait should be avoided have not been clearly delineated because evidence from controlled studies is lacking. AABB standards require each transfusion service to establish a policy that describes when to avoid transfusion of sickle cell trait erythrocyte.

This Guideline reviews the various recommendations being made in the absence of controlled studies, and critically examines the basis for them.

Topics include:

Evidence regarding problems with transfusion of Hb AS blood
Formulating a policy for transfusion of sickle cell trait erythrocytes
Test methods for detection of sickle hemoglobin

Microcirculatory Effects of Hemoglobin Solutions: 17th Bodensee Symposium on Microcirculation, Lindau, June 21-23, 2002 (Progress in Applied Microcirculation)
by K. Messmer (Editor), K. E. Burhop (Editor), J. Hutter (Editor)

Solutions of stroma-free hemoglobin have been investigated for their potential as blood replacement fluids for more than 70 years. Despite many attempts to overcome their unwanted side effects through chemical modification of the hemoglobin molecule, none of the potential solutions has been approved for clinical use in Europe or the United States. In recent years, the vasoconstrictive activity of hemoglobin in the plasma was identified as the pivotal problem of hemoglobin-based blood substitutes, compromising nutritional perfusion and thus impeding oxygen unloading at the site of the microcirculation. One of the prevailing assumptions is that the precapillary vasoconstriction and the ensuing tissue underperfusion is caused by the high affinity of free hemoglobin for nitric oxide. To...

Hemoglobin Function in Vertebrates: Molecular Adaptation in Extreme and Temperate Environments
by G. di Prisco (Editor), B. Giardina (Editor), R.E. Weber (Editor)

This volume comprises selected contributions by internationally renowned researchers and represents the state-of-the-art in the field of hemoglobin function in vertebrates living in extreme and temperate environments. The topics have been covered from several viewpoints, including protein chemistry, molecular biology, and evolution. All the contributions chosen for publication focus on phenotypic and genetic adaptations to changing environmental conditions and on gene expression and regulation. The book provides the reader with an update in this field, which is presently enjoying a true renaissance following developments in recent years of powerful methodologies such as site-directed mutagenesis and discoveries of new roles, for example, as oxygen sensors and in nitric oxide metabolism.